- Home
- TLSA vs ALVR Comparison
TLSA vs ALVR Comparison
Compare TLSA & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- ALVR
- Stock Information
- Founded
- TLSA 2013
- ALVR 2013
- Country
- TLSA United Kingdom
- ALVR United States
- Employees
- TLSA N/A
- ALVR N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLSA Health Care
- ALVR Health Care
- Exchange
- TLSA Nasdaq
- ALVR Nasdaq
- Market Cap
- TLSA 87.8M
- ALVR 87.7M
- IPO Year
- TLSA 2000
- ALVR 2020
- Fundamental
- Price
- TLSA $1.20
- ALVR $0.90
- Analyst Decision
- TLSA
- ALVR Sell
- Analyst Count
- TLSA 0
- ALVR 5
- Target Price
- TLSA N/A
- ALVR $1.00
- AVG Volume (30 Days)
- TLSA 145.8K
- ALVR 155.6K
- Earning Date
- TLSA 05-10-2024
- ALVR 11-04-2024
- Dividend Yield
- TLSA N/A
- ALVR N/A
- EPS Growth
- TLSA N/A
- ALVR N/A
- EPS
- TLSA N/A
- ALVR N/A
- Revenue
- TLSA N/A
- ALVR N/A
- Revenue This Year
- TLSA N/A
- ALVR N/A
- Revenue Next Year
- TLSA N/A
- ALVR N/A
- P/E Ratio
- TLSA N/A
- ALVR N/A
- Revenue Growth
- TLSA N/A
- ALVR N/A
- 52 Week Low
- TLSA $0.41
- ALVR $0.58
- 52 Week High
- TLSA $1.74
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- TLSA 65.44
- ALVR 69.10
- Support Level
- TLSA $0.83
- ALVR $0.74
- Resistance Level
- TLSA $0.92
- ALVR $0.91
- Average True Range (ATR)
- TLSA 0.09
- ALVR 0.06
- MACD
- TLSA 0.03
- ALVR 0.01
- Stochastic Oscillator
- TLSA 84.52
- ALVR 94.50
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.